Patients with febrile neutropenia are at a high risk of contracting the coronavirus infection.
Regular Patient Monitoring Reduces Stress on Clinicians amidst COVID-19 Outbreak
Patients with febrile neutropenia are at a high risk of contracting the coronavirus (COVID-19) infection. Hence, pharma companies in the febrile neutropenia market are increasing their production capabilities to manufacture intravenous (IV) antibiotics to avoid supply shocks in healthcare settings. Manufacturers are educating clinicians to conduct regular computed tomography (CT) scan of the chest of febrile neutropenia patients even in the absence of cough. This helps in early detection of COVID-19, and helps to effectively manage the symptoms at an early stage.
Moreover, cancer patients with neutropenia complications are susceptible to coronavirus. In order to tide over uncertainties stemming from the pandemic, companies in the febrile neutropenia market are increasing their focus in pediatric cancer patient care. Only patients with high risk or immediate risk are recommended with the granulocyte-colony stimulating factor (G-CSF) therapy to maintain stocks in healthcare facilities.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2857
Collaborative Inter-professional Team Approach Helps Improve Medical Outcomes
The oral empiric therapy with a fluoroquinolone plus amoxicillin/clavulanate is considered as the gold standard in the treatment of low-risk febrile neutropenia patients. However, limitations in chemotherapy-induced neutropenia assessment tools such as the Clinical Index of Stable Febrile Neutropenia (CISNE) score model are hindering the growth of the febrile neutropenia market. Hence, pharma companies must collaborate with infectious disease specialists to improve medical outcomes in oncology emergency settings.
Manufacturers in the febrile neutropenia market should increase their R&D capabilities to develop improved formulations of IV antibiotics, as early admission of antibiotics has clinically helped to reduced mortality rates and minimize the time spent in hospitals. Pharmacists should work as a collaborative inter-professional team with clinicians to assist in antibiotic selection and dosing. There is a need for proper training of the nursing staff to monitor and report any changes taking place during the treatment.
Request for Analysis of COVID-19 Impact on Febrile Neutropenia Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2857
Companies Collaborate with Multidisciplinary Research Teams to Decrease Occurrence of Infection
The treatment received by advanced cancer patients tends to weaken their immune systems and increases the risk of life-threatening infections such as febrile neutropenia. Hence, companies in the febrile neutropenia market are capitalizing on this opportunity to boost the availability of FDA (Food and Drug Administration)-approved drugs. However, lack of clear standard care pertaining to the patients and medicines has led to undetermined levels of risk. Hence, pharmaceutical manufacturers are collaborating with researchers at universities to determine the quality and safety of FDA-approved medications.
Companies are increasing efforts to gather data from over several thousands of cancer patients by setting up multidisciplinary research teams. This helps pharmaceutical manufacturers in the febrile neutropenia market to gain granular details into the rate of occurrence for the infection.
Pre Book Febrile Neutropenia Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=2857<ype=S
Artificial Intelligence Algorithms Give Rise to Personalized Infection Control Practices
Apart from FDA-approved medications, companies in the febrile neutropenia market are focusing on traditional measures such as the patient skincare, hand hygiene, central venous catheter care, and the likes to broaden their revenue streams. Manufacturers are innovating in products that deliver environmental protection, as febrile neutropenia patients are found to have a weak immune system. However, multidrug-resistant organisms (MDRO) are being reported in patients and is emerging as a challenge for pharmaceutical manufacturers. Hence, companies are using new technologies such as decolonization and the use of predictive models for the infection.
In addition, the proliferation of artificial intelligence (AI) algorithms has led to the trend of personalized infection control practices. Thus, companies in the febrile neutropenia market are gaining a strong research base in AI technologies to deliver better outcomes after IV antibiotics administration in patients.
Read more information here:
https://www.transparencymarketresearch.com/febrile-neutropenia-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453